Onconetix (Onconetix) Cash-to-Debt : 0.29 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Onconetix Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Onconetix's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.29.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Onconetix couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Onconetix's Cash-to-Debt or its related term are showing as below:

ONCO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29 Med: No Debt Max: No Debt
Current: 0.29

During the past 5 years, Onconetix's highest Cash to Debt Ratio was No Debt. The lowest was 0.29. And the median was No Debt.

ONCO's Cash-to-Debt is ranked worse than
89.86% of 1528 companies
in the Biotechnology industry
Industry Median: 6.315 vs ONCO: 0.29

Onconetix Cash-to-Debt Historical Data

The historical data trend for Onconetix's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Onconetix Cash-to-Debt Chart

Onconetix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

0.46

Onconetix Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial											No Debt	0.70	0.59	0.46	0.29

Competitive Comparison of Onconetix's Cash-to-Debt

For the Biotechnology subindustry, Onconetix's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Onconetix's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Onconetix's Cash-to-Debt falls into.

Onconetix Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Onconetix's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.554	/	(9.693	+	0.193)
	=	0.46

Onconetix's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.464	/	(15.244	+	0.158)
	=	0.29

Onconetix (NAS:ONCO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Onconetix Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Onconetix's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Onconetix (Onconetix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

J4T:Germany

Address

201 East Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202

Website

https://www.onconetix.com

Onconetix Inc is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has a product named Entadfi an FDA approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Executives

Neil J Campbell	director, officer: Chief Executive Officer	225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Bruce Harmon	officer: Chief Financial Officer	316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Timothy R. Ramdeen	director	201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Vuk Jeremic	director	BLUE WATER VACCINES INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
Cincinnati Cornerstone Investors Bwv I, Llc	10 percent owner	2900 READING ROAD, SUITE 410, CINCINNATI OH 45206
Cincinnati Cornerstone Capital Llc	other: Manager-Cinti Cornerstone Inv.	2900 READING RD, SUITE 410, CINCINNATI OH 45206
Joseph Hernandez	10 percent owner, officer: CEO	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Simon Tarsh	director	201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Allan Shaw	director	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Erin Henderson	officer: Chief Business Officer	201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Rice John Mccune Jr.	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jon Garfield	officer: CFO	11111 SANTA MONICA BLVD., SUITE 650, LOS ANGELES CA 90025
Michael Venerable	director	201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202